The purpose of this study was to determine the effectiveness of trastuzumab in the local population having HER-2 overexperssion, so that it can be used as a reference for future studies.
METHODOLOGY
The study was a retrospective, observational double-arm study. All patients receiving trastuzumab in neoadjuvant setting at Shaukat Khanum Memorial Cancer Hospital from 2008 to August 2016, fulfilling the inclusion criteria, were observed. The study protocols were reviewed by the Institutional Review Board and exemption was taken for informed consent as no direct interaction with patients was involved. Medical records were reviewed from the computer based hospital information system. The pre-aimed primary endpoint was to compare the pCR in HER-2 overexpressing breast cancer patients getting NACT with or without trastuzumab. The secondary endpoints were to study the frequency of breast conservation in patients getting trastuzumab preoperatively along with chemotherapy irrespective of the PCR; and added toxicities and influence of other baseline characteristics. Locally advanced HER2-positive breast cancer patients with cytologically proven axillary nodes receiving standard NACT with or without trastuzumab were studied. A normal cardiac function had been documented at baseline by echocardiography; and cardiology opinion was taken for borderline cases before administration of trastuzumab, as it has a documented side effect of cardiotoxicity. Patients received four cycles of trastuzumab 6mg/kg intravenously every 3 weeks, starting from a loading dose of 8mg/kg in the first cycle or 12 doses of 2mg/kg weekly with a loading dose of 4mg/kg in the first cycle concomitantly with taxane-based therapy. Pathological complete response (pCR) was defined as no residual invasive or in situ residual tumor in breast tissue, or in the lymph nodes. 14 Toxicities were assessed according to National Cancer Institute Common Terminology Criteria version 4.0. Lumpectomy or quadrantectomy and segmentectomy were stated as breast conservation procedures.
Data was collected through the computer-based Hospital Information System (HIS). Statistical analysis was performed by using SPSS version 20. For categorical variables, percentages (proportions) were reported as shown in Table I and II. Bivariate analysis was done using Chi-square or Fisher exact test, wherever appropriate, to establish the association between two categorical variables with p<0.05 considered as statistically significant. Univariable analysis was done to establish the relationship of one explanatory variable at a time with the outcome variable. The odds ratio, confidence interval, and p-value were calculated for each variable and reported in Table III column 4. In the multivariable analysis, statistical analysis was done by using step-wise regression method. All the factors with p<0.05 were considered statistically significant independent risk factors affecting pathological complete response. The odds ratio, confidence interval, and p-value were calculated for each variable and reported in Table III 
RESULTS
During the study period, 89 patients with HER2-positive disease received trastuzumab preoperatively. Twenty patients (22.5%) could not get the complete planned cycles of trastuzumab preoperatively due to financial reasons or delayed approval while surgery could not be done in one (1.12%) patient due to disease progression while on therapy. Four (4.5%) patients had to undergo surgery earlier due to poor tolerance of chemotherapy. The study group, therefore, comprised 64 (n=64) patients who received full dose of neoadjuvant trastuzumab.
The overall pCR in entire population was (n=48) 36.6%. The pCR of the patients who received trastuzumab in the neoadjuvant setting was (n=32) 50%, which was 26.1% higher than the reference group (n=16) 23.9%. This difference was statistically significant with a p-value of 0.002 (<0.05). Breast conservation was possible in 57 (43.51%) patients in total and 51.56% in patients getting trastuzumab preoperatively as compared to 35.82% in patients who received chemotherapy alone. P-value was calculated as 0.69 which although was not statistically significant, but still a considerable number of patients had a less extensive surgery.
Toxicities were documented according to National Cancer Institute Common Toxicity Criteria (version 4.0) grading of adverse events by reviewing the records in the computer-based Hospital Information System. By adding trastuzumab, there were no major differences in the toxicity profiles of both groups as shown in Table II . The drop in ejection fraction, which is a major concern with the addition of trastuzumab, was also almost equal in both groups with no major differences. No patient developed symptomatic heart failure and none had to stop trastuzumab before completing the planned therapy.
DISCUSSION
This study demonstrated that HER2-positive (overexpressing) breast cancer patients, who received preoperative trastuzumab in combination with standard chemotherapeutic regimens, achieved significantly higher rates of pCR as compared to those who got chemotherapy alone. According to protocol pre-defined definition the pCR in entire patient population was 36.6%. Patients who received trastuzumab in the neoadjuvant setting had pCR of 50%, which was 26.1% higher than the reference group (23.9%), which is almost double in comparison. This response is significantly higher than the previously conducted international studies like GparQuattro study having a complete response rate of 31.7% in patients getting preoperative trastuzumab. 15 Similarly, transtuzumab in neoadjuvant setting in newly diagnosed locally advanced HER2-positive breast cancer patients has been studied in TECHNO trial which was a phase II single-arm study which showed a complete response rate of 39%. 16 The NOAH trial demonstrated a pCR rate of 43% in neoadjuvant trastuzumab combination group as compared to 22% in the chemotherapy alone group. 17 A recent study in the local population demonstrated the similar response rates of 54.8% comparable to this study population. 18 Compared to all the above mentioned studies, this study has demonstrated a notably high pCR in these patients and can be future perspective for further studies. One possible reason for the better response can be the factor that all node-positive patients were included, depicting a better response in this high risk population. Although a single study at an individual centre with a small number of patients cannot be a true representative of the entire population, it definitely provides an insight for more studies so that possible causes of increased response in the local population can be studied. Different mechanisms of resistance to trastuzumab therapy have been studied including loss of PTEN and are thought to promote tumorigenesis by activating PI3K signalling pathway. 19 Since this study population has demonstrated a quite high response, studies are needed to look for genetic factors in our people which render our patients more susceptible to response to trastuzumab-based therapy like PTEN expression. 20 Although the study demonstrated a significantly higher pathological response in the neoadjuvant trastuzumab group, breast conservation rate was not significantly different in both the patient groups, but less extensive surgery was possible in notable number of patients. Regarding toxicity profile, the addition of trastuzumab to standard chemotherapeutic regimens did not significantly increase the toxicity profile as compared to chemotherapy alone. This study has several weaknesses. Firstly, it is a retrospective study, so all patients did not receive similar chemotherapeutic regimens. However, this was uniform for both study arms. It included a small number of patients; had it included a greater number of patients, results would have been more powerful. However, since all patients fulfilling the inclusion criteria were included, so there was no selection bias. Hence, results are likely depictive of response in our population.
CONCLUSION
Combining trastuzumab with standard chemotherapy regimens in HER2-positive achieves significantly higher rate of pathological complete response without clinically significant increased toxicity. Further studies with larger number of patients are required to demonstrate mechanisms leading to better responses in this population and whether this increased response can be translated into increased survival rates.
